About Andrew
Andrew is recognised as one of the leading Defamation Lawyers in the country.
Andrew has unrivalled experience in advising high profile political figures on national and international reputational issues.
He has dealt with many leading High Court cases where jurisdiction has been in issue, including Papandreou v Time Magazine, Bachchan v Dagens Nyheter, Schapira v Ahronson, Berezovsky v Forbes and Jameel v Dow Jones.
Andrew has worked with lawyers from many countries, including the US, Russia, France, Switzerland, Sweden, Denmark, Saudi Arabia, Nigeria, Brazil and China. He has also had notable successes defending individuals who have been sued for defamation by wealthy claimants.
He acted for the Danish professor Henrik Thomsen when he was sued by the US, UK and Norwegian GE Healthcare companies and for Sarah Hermitage when she was sued by a Tanzanian multi-millionaire, Reginald Mengi. Andrew has also advised book, magazine and newspaper publishers and television companies on matters of libel, privacy and the law of contempt.
Andrew was a member of the Ministry of Justice working group set up in 2010 to consider reform of libel law, which led to the Defamation Act 2013.
Andrew is recognised by Chambers and Partners as a Ranked Lawyer for defamation/reputation management.
Andrew is recognised by Legal 500 as Recommended Lawyer for reputation management.
Work Highlights
- From 2012 until 2014, Andrew defended Sarah Hermitage, when she faced a libel claim over a blog in which she recounted how she and her husband had been forced by corruption and intimidation to abandon a farm they had established in Tanzania; the court ruled in her favour and found the claimant and his witnesses to have given evidence which was misleading and untrue
- From 1997 Andrew represented the Russian businessman Boris Berezovsky until his death in 2013, advising on media issues and defending him against two sets of extradition proceedings.
- From 2008 until the case was settled in 2010, he acted for the Danish Professor Henrik Thomsen, who was sued for libel after he had raised well-founded suspicions of a link between a pharmaceutical product and the rare but serious disease, nephrogenic systemic fibrosis.